source
- Arpeggio plays final chord as biotech disbands on poor prospects for Nrf2 programArpeggio Biosciences’ eight-year song has come to an end, as the transcriptome biotech’s CEO admitted the that company’s Nrf2 program had begun to “unravel.”Fierce Biotech · 22h ago↗ source
- Silence brings the noise to Takeda with phase 2 blood cancer winA phase 2 trial of Silence Therapeutics’ divesiran has hit its primary endpoint, emboldening the biotech to gear up for late-phase development of a potential challenger to Takeda and Protagonist Th…Fierce Biotech · 23h ago↗ source
- aTyr lays off 60% of workforce to fund 2nd attempt at phase 3 success for lung disease drugSixty per cent of aTyr Pharma’s workforce are heading for the exits as the biotech conserves resources for a second shot at phase 3 success in a type of lung disease.